Maxim Group Reaffirms “Buy” Rating for Hemispherx BioPharma (NYSEAMERICAN:HEB)

Maxim Group restated their buy rating on shares of Hemispherx BioPharma (NYSEAMERICAN:HEB) in a research report released on Friday morning, AnalystRatings.com reports. They currently have a $8.00 target price on the specialty pharmaceutical company’s stock.

“Hemispherx Biopharma announced positive safety and survival results from its Phase 1/2 trial evaluating Ampligen use as a combination therapy in recurrent ovarian cancer. Recall that the trial, conducted by the Center (UPMC), comprised of administering Ampligen in combination with Intron A and celecoxib via intraperitoneal delivery to patients with stage 4 ovarian cancer. No safety signals were observed. Focus turns to the ongoing phase 2 study in the recurrent ovarian cancer. which is also being conducted at UPMC. This trial is evaluating Ampligen, keytruda and cisplatin combination.”,” the firm’s analyst commented.

Separately, Ascendiant Capital Markets set a $44.00 target price on Hemispherx BioPharma and gave the company a buy rating in a report on Friday, May 17th.

Shares of HEB opened at $1.88 on Friday. Hemispherx BioPharma has a fifty-two week low of $1.69 and a fifty-two week high of $14.81.

Hemispherx BioPharma (NYSEAMERICAN:HEB) last issued its earnings results on Thursday, May 16th. The specialty pharmaceutical company reported ($3.08) earnings per share for the quarter.

In other Hemispherx BioPharma news, Director William M. Mitchell bought 9,677 shares of the company’s stock in a transaction dated Friday, June 21st. The shares were bought at an average price of $4.03 per share, for a total transaction of $38,998.31. Following the acquisition, the director now directly owns 20,838 shares of the company’s stock, valued at $83,977.14. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Thomas K. Equels bought 29,404 shares of the company’s stock in a transaction dated Friday, June 21st. The stock was acquired at an average price of $4.03 per share, for a total transaction of $118,498.12. Following the acquisition, the insider now directly owns 1,393,611 shares in the company, valued at $5,616,252.33. The disclosure for this purchase can be found here. Insiders bought a total of 46,924 shares of company stock worth $189,999 in the last quarter.

About Hemispherx BioPharma

Hemispherx Biopharma, Inc, a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS).

Featured Article: Capital gains and your 401(k) or IRA

Receive News & Ratings for Hemispherx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.